US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Precision BioSciences, Inc. - Common Stock
(NQ:
DTIL
)
6.790
+0.380 (+5.93%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Precision BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
October 08, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
August 24, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences (NASDAQ:DTIL) Passes Minervini Trend Template and High-Growth Momentum Screen
↗
August 08, 2026
Via
Chartmill
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 06, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
July 31, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
July 27, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
June 29, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
These stocks are gapping in today's session
↗
June 08, 2026
Via
Chartmill
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
May 27, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
May 21, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
May 14, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 05, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
April 30, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
April 28, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
April 22, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
April 15, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 08, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
March 12, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
March 11, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
March 10, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
March 09, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
March 09, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
March 02, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
February 18, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
February 11, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
January 12, 2026
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2025
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
